Drug Trial Radar · NCT04657198
Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Last checked: Nov 20, 2026Latest source record: Jun 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Dec 9, 2020
Primary completion
Jun 3, 2021
Study completion Oct 25, 2021
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Nine different formulations of the RSVPreF3 OA investigational vaccine were tested in the parent study (NCT03814590). Based on safety and immunogenicity data from the parent study, RSVPreF3 OA investigational vaccine will be evaluated in further clinical research. Participants in selected groups will be invited to participate in this extension study. All participants who will be enrolled in the current extension study will receive the RSV investigational vaccine approximately 18 months after they received their respective dose-2 in the parent study.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine (GSK3844766A)Biological
RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Solicited Administration Site Adverse Events (AEs)Time frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
- Number of Participants With Any Solicited Systemic AEsTime frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
- Number of Participants With Any Unsolicited AEsTime frame: During the 30-day follow-up period post-vaccination (i.e., on the day of vaccination [Day 1] and 29 subsequent days)
- Number of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccinationTime frame: From Day 1 up to 30 days post-vaccination (Day 31)
- Number of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccinationTime frame: From Day 1 up to 30 days post-vaccination (Day 31)
- Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype ATime frame: At 30 days post-vaccination (Day 31)
- Humoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype BTime frame: At 30 days post-vaccination (Day 31)
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Lenexa, Kansas
GSK Investigational Site
Elkridge, Maryland
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Hickory, North Carolina
GSK Investigational Site
Mt. Pleasant, South Carolina
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Wilrijk, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.